{"corpus_id":16963349,"paper_sha":"26bb66eb72941dcfe89fc7943d90e10b7f2174d3","doi":"10.1186/s40425-015-0067-z","arxiv_id":null,"pmid":25992292,"pmcid":"4437699","mag_id":1543079591,"dblp_id":null,"acl_id":null,"title":"Combination immunotherapy with α-CTLA-4 and α-PD-L1 antibody blockade prevents immune escape and leads to complete control of metastatic osteosarcoma","year":2015,"publication_date":"2015-05-19","venue":"Journal of Immunotherapy for Cancer","journal":{"name":"Journal for Immunotherapy of Cancer","pages":null,"volume":"3"},"journal_issn":null,"journal_title":null,"publication_types":["JournalArticle"],"pubmed_pub_types":["Journal Article"],"s2_fields_of_study":["Medicine"],"reference_count":47,"citation_count":194,"influential_citation_count":4,"is_open_access":true,"arxiv_categories":null,"arxiv_license":null,"arxiv_journal_ref":null,"mesh_headings":null,"chemicals":null,"comments_corrections":null,"source_flags":5,"s2_open_access_pdf_url":"https://jitc.bmj.com/content/jitc/3/1/21.full.pdf","s2_open_access_landing_url":"https://www.semanticscholar.org/paper/26bb66eb72941dcfe89fc7943d90e10b7f2174d3","s2_open_access_license":"CCBYNCND","s2_open_access_status":"GOLD","pmc_open_access_pdf_url":null,"pmc_open_access_landing_url":null,"pmc_open_access_license":null,"pmc_open_access_status":null,"unpaywall_open_access_pdf_url":null,"unpaywall_open_access_landing_url":null,"unpaywall_open_access_license":null,"unpaywall_open_access_status":null,"abstract":"BackgroundOsteosarcoma is one of the most common bone cancers in children. Most patients with metastatic osteosarcoma die of pulmonary disease and limited curative therapeutic options exist for such patients. We have previously shown that PD-1 limits the efficacy of CTL to mediate immune control of metastatic osteosarcoma in the K7M2 mouse model of pulmonary metastatic disease and that blockade of PD-1/PD-L1 interactions can partially improve survival outcomes by enhancing the function of osteosarcoma-specific CTL. However, PD-1/PD-L1 blockade-treated mice eventually succumb to disease due to selection of PD-L1 mAb-resistant tumor cells. We investigated the mechanism of tumor cell resistance after blockade, and additional combinational therapies to combat resistance.MethodsWe used an implantable model of metastatic osteosarcoma, and evaluated survival using a Log-rank test. Cellular analysis of the tumor was done post-mortem with flow cytometry staining, and evaluated using a T-test to compare treatment groups.ResultsWe show here that T cells infiltrating PD-L1 antibody-resistant tumors upregulate additional inhibitory receptors, notably CTLA-4, which impair their ability to mediate tumor rejection. Based on these results we have tested combination immunotherapy with α-CTLA-4 and α-PD-L1 antibody blockade in the K7M2 mouse model of metastatic osteosarcoma and show that this results in complete control of tumors in a majority of mice as well as immunity to further tumor inoculation.ConclusionsThus, combinational immunotherapy approaches to block additional inhibitory pathways in patients with metastatic osteosarcoma may provide new strategies to enhance tumor clearance and resistance to disease.","claims":[{"public_id":"cl_2c1a2f41b48bdff0cdbc9791d0186a1b","status":"active","text":"Combination immunotherapy with α-CTLA-4 and α-PD-L1 antibody blockade results in complete control of tumors in a majority of mice and immunity to further tumor inoculation in the K7M2 mouse model of metastatic osteosarcoma.","confidence":0.95,"contributors":[{"id":32,"public_id":"7c402c1b98","public_label":"뀨 (7c402c1b98)","roles":["extraction"],"url":"https://sah.borca.ai/u/7c402c1b98"},{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["review"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/claims/cl_2c1a2f41b48bdff0cdbc9791d0186a1b"},{"public_id":"cl_6fd007485e42ebe4faa452a26495a025","status":"active","text":"PD-1/PD-L1 blockade-treated mice eventually succumb to disease due to selection of PD-L1 mAb-resistant tumor cells.","confidence":0.9,"contributors":[{"id":32,"public_id":"7c402c1b98","public_label":"뀨 (7c402c1b98)","roles":["extraction"],"url":"https://sah.borca.ai/u/7c402c1b98"},{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["review"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/claims/cl_6fd007485e42ebe4faa452a26495a025"},{"public_id":"cl_c13e48573bb752694d3dc710fb795893","status":"active","text":"T cells infiltrating PD-L1 antibody-resistant tumors upregulate additional inhibitory receptors, notably CTLA-4, which impair their ability to mediate tumor rejection.","confidence":0.95,"contributors":[{"id":32,"public_id":"7c402c1b98","public_label":"뀨 (7c402c1b98)","roles":["extraction"],"url":"https://sah.borca.ai/u/7c402c1b98"},{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["review"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/claims/cl_c13e48573bb752694d3dc710fb795893"}],"concepts":[{"public_id":"co_2efbd3b6f8b86c0b729c967aaed4526a","status":"active","name":"α-PD-L1 antibody blockade","description":"Antibody that blocks PD-L1, used in combination with α-CTLA-4 in this study.","types":["antibody","therapeutic agent"],"aliases":["anti-PD-L1 antibody"],"contributors":[{"id":32,"public_id":"7c402c1b98","public_label":"뀨 (7c402c1b98)","roles":["extraction"],"url":"https://sah.borca.ai/u/7c402c1b98"},{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["review"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_2efbd3b6f8b86c0b729c967aaed4526a"},{"public_id":"co_34da2c3181ad1f09b70b68647d1353eb","status":"active","name":"α-CTLA-4","description":"Antibody that blocks CTLA-4, used in combination with α-PD-L1 in this study.","types":["antibody","therapeutic agent"],"aliases":["anti-CTLA-4 antibody"],"contributors":[{"id":32,"public_id":"7c402c1b98","public_label":"뀨 (7c402c1b98)","roles":["extraction"],"url":"https://sah.borca.ai/u/7c402c1b98"},{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["review"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_34da2c3181ad1f09b70b68647d1353eb"},{"public_id":"co_4c6db59d5aabdbdba7da6f1a8dd8f212","status":"active","name":"K7M2 mouse model","description":"An implantable mouse model of metastatic osteosarcoma used to evaluate combination immunotherapy.","types":["animal model"],"aliases":[],"contributors":[{"id":32,"public_id":"7c402c1b98","public_label":"뀨 (7c402c1b98)","roles":["extraction"],"url":"https://sah.borca.ai/u/7c402c1b98"},{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["review"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_4c6db59d5aabdbdba7da6f1a8dd8f212"},{"public_id":"co_5b498424e9f97ceacaa9f83cb2103af2","status":"active","name":"PD-L1 mAb-resistant tumor cells","description":"Tumor cells selected after PD-L1 blockade treatment that are resistant to the monoclonal antibody.","types":["resistance phenotype"],"aliases":[],"contributors":[{"id":32,"public_id":"7c402c1b98","public_label":"뀨 (7c402c1b98)","roles":["extraction"],"url":"https://sah.borca.ai/u/7c402c1b98"},{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["review"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_5b498424e9f97ceacaa9f83cb2103af2"},{"public_id":"co_64453ef1105fabd755cf007847119fa9","status":"active","name":"combination immunotherapy","description":"Therapeutic approach combining α-CTLA-4 and α-PD-L1 antibody blockade to block multiple inhibitory pathways.","types":["treatment strategy"],"aliases":["combinational immunotherapy"],"contributors":[{"id":32,"public_id":"7c402c1b98","public_label":"뀨 (7c402c1b98)","roles":["extraction"],"url":"https://sah.borca.ai/u/7c402c1b98"},{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["review"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_64453ef1105fabd755cf007847119fa9"},{"public_id":"co_8379c632bbd57cec16b5b9eaaf696bc1","status":"active","name":"PD-1/PD-L1 blockade","description":"Immunotherapy that blocks PD-1/PD-L1 interactions to enhance CTL function, but leads to resistance in this model.","types":["immunotherapy approach"],"aliases":[],"contributors":[{"id":32,"public_id":"7c402c1b98","public_label":"뀨 (7c402c1b98)","roles":["extraction"],"url":"https://sah.borca.ai/u/7c402c1b98"},{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["review"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_8379c632bbd57cec16b5b9eaaf696bc1"},{"public_id":"co_837e0c9f453e1a2d71c8c4c30d2f58bf","status":"active","name":"PD-L1 antibody-resistant tumors","description":"Tumor cells that have become resistant to PD-L1 monoclonal antibody treatment, leading to escape from immune control.","types":["phenotype","resistance mechanism"],"aliases":["PD-L1 mAb-resistant tumor cells"],"contributors":[{"id":32,"public_id":"7c402c1b98","public_label":"뀨 (7c402c1b98)","roles":["extraction"],"url":"https://sah.borca.ai/u/7c402c1b98"},{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["review"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_837e0c9f453e1a2d71c8c4c30d2f58bf"},{"public_id":"co_95b49ef0668c1b88b86834adee33af53","status":"active","name":"CTLA-4","description":"An inhibitory receptor upregulated on T cells infiltrating PD-L1 antibody-resistant tumors, impairing tumor rejection.","types":["protein","immune checkpoint receptor"],"aliases":["cytotoxic T-lymphocyte-associated protein 4"],"contributors":[{"id":32,"public_id":"7c402c1b98","public_label":"뀨 (7c402c1b98)","roles":["extraction"],"url":"https://sah.borca.ai/u/7c402c1b98"},{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["review"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_95b49ef0668c1b88b86834adee33af53"},{"public_id":"co_987af6fb5f785353e500bbca56ab760a","status":"active","name":"tumor rejection","description":"The ability of T cells to mediate elimination of tumor cells.","types":["immune process"],"aliases":[],"contributors":[{"id":32,"public_id":"7c402c1b98","public_label":"뀨 (7c402c1b98)","roles":["extraction"],"url":"https://sah.borca.ai/u/7c402c1b98"},{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["review"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_987af6fb5f785353e500bbca56ab760a"},{"public_id":"co_a615979b66670440fee36a85d004c9be","status":"active","name":"metastatic osteosarcoma","description":"A common bone cancer in children that spreads to the lungs, studied in the K7M2 mouse model.","types":["cancer type"],"aliases":[],"contributors":[{"id":32,"public_id":"7c402c1b98","public_label":"뀨 (7c402c1b98)","roles":["extraction"],"url":"https://sah.borca.ai/u/7c402c1b98"},{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["review"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_a615979b66670440fee36a85d004c9be"}],"external_ids":{"DOI":"10.1186/s40425-015-0067-z","ArXiv":null,"PubMed":25992292,"PubMedCentral":"4437699","MAG":1543079591,"DBLP":null,"ACL":null},"open_access":{"is_open_access":true,"pdf_url":"https://jitc.bmj.com/content/jitc/3/1/21.full.pdf","landing_url":"https://www.semanticscholar.org/paper/26bb66eb72941dcfe89fc7943d90e10b7f2174d3","source":"semantic_scholar","pdf_url_source":"semantic_scholar_open_access_pdf","license":"CCBYNCND","status":"GOLD","reason":null},"reference_availability":{"status":"available","references_indexed":true,"full_text_available":false,"full_text_source":null,"count_basis":"semantic_scholar_metadata","extraction_status":"not_applicable","reason":null},"source":{"provider":"episteme2","base_corpus":"semantic_scholar_dump","freshness_mode":"unknown","basis":["semantic_scholar_metadata","postgres_metadata"],"limits":["paper metadata is based on indexed upstream scholarly datasets","claims and concepts are available only for extracted papers","absence of claims or concepts means no extracted graph data is available in this response"],"status":"available","degraded":false,"degraded_reasons":[],"diagnostics":{"status":"available","degraded":false,"degraded_reasons":[],"metadata_status":"available","graph_status":"available","abstract_status":"available"},"source_flags":5},"paper_id":637490,"paper_uid":"ecc5bfdd-2299-4678-afb3-9a3694237a06","canonical_identity":{"paper_id":637490,"paper_uid":"ecc5bfdd-2299-4678-afb3-9a3694237a06","identity_status":"available","lookup_basis":"semantic_scholar_external_id","compatibility_path":"corpus_id"},"url":"https://sah.borca.ai/papers/16963349"}